Sage Therapeutics, Inc. (SAGE)
| Market Cap | 4.38B |
| Revenue (ttm) | 1.11B |
| Net Income (ttm) | 637.05M |
| Shares Out | 58.37M |
| EPS (ttm) | 11.66 |
| PE Ratio | 6.42 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 10 |
| Last Price | $74.89 |
| Previous Close | $75.07 |
| Change ($) | -0.18 |
| Change (%) | -0.24% |
| Day's Open | 74.10 |
| Day's Range | 72.64 - 75.99 |
| Day's Volume | 282,880 |
| 52-Week Range | 33.82 - 98.38 |
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 17.17% and -18.78%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with de...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with de...
Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have scored their first but narrow win after signing their $3.1 billion deal last year in November. SAGE-324, the second major molecule...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today reported topline results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatmen...
Gilead Sciences, Biogen and Vertex Pharmaceuticals could top expectations in an otherwise soft quarter for biotech stocks, an analyst said Thursday. He sees key products beating forecasts.
Investors need to pay close attention to Sage Therapeutics (SAGE) stock based on the movements in the options market lately.
Though these stocks have dropped, upcoming news offers hope for them to rebound.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with de...
Can this brain health-focused biotech continue to rise, or will it fade -- again?
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) today reported complete 12-month data from the 30 mg cohort and interim data from the 50 mg cohort of the ongoing Phase 3 open-l...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilita...
A Relative Strength Rating upgrade for Sage Therapeutics shows improving technical performance. The post Sage Therapeutics Shows Rising Price Performance With Jump To 81 RS Rating appeared first on Inve...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the ...
Sage Therapeutics, Inc. (SAGE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Sage Therapeutics, Inc. (SAGE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives o...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives o...
American BriVision: Deep Dive Into Market Potential
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives o...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives o...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of peop...
Naughty or nice, shareholders aren't getting anything on their wish lists from these stocks this year.
Biogen recently announced a $1.5 billion collaboration agreement with Sage Therapeutics. Despite an earlier failed trial, Zuranolone is a promising therapy for depression.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of...
The shares of Sage Therapeutics Inc (NASDAQ:SAGE) are down 1.8% at $72.78 at last check, after Raymond James downgraded the stock to "Market Perform" from "Outperform," following its recent $1.5 billion...
Biogen (BIIB) and Sage Therapeutics (SAGE) collaborate to develop latter's zuranolone for depression indications and SAGE-324 for essential tremor.
Biogen Inc. and Sage Therapeutics Inc. said Monday they have agreed to jointly develop therapies to treat depression and movement disorders in a deal in which Biogen will give Sage $1.525 billion in cas...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced that they have executed a global collaboration and license agreement to...
Sage Therapeutics' (SAGE) Management on Q3 2020 Results - Earnings Call Transcript
Shares of Sage Therapeutics (NASDAQ: SAGE) were unchanged after the company reported Q3 results. Quarterly Results Earnings per share increased 41.67% year over year to ($2.03), which beat the estimate ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives o...
Sage Therapeutics has shown impressive results on the charts YTD, where shareholders have enjoyed +169% gains since the selloff. The stock has bounced away from support nicely 5 times since then, with n...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives o...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives o...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives o...
Sage Therapeutics (SAGE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
With depression rates up amid the economic and health crises, mental health should be treated like a physical illness, Sage Therapeutics CEO Jeff Jonas said on "Mad Money."
Sage Therapeutics CEO: Mental health is integral to returning to work
"We need to treat mental health like a physical illness, treat it urgently, in order to get people back to work and back to their families," Sage Therapeutics CEO Jeff Jonas said.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Today, Sage Therapeutics, Inc.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc.
Sage Therapeutics, Inc. (SAGE) CEO Jeffrey Jonas on Q2 2020 Results - Earnings Call Transcript
Shares of Sage Therapeutics (NASDAQ:SAGE) were flat in pre-market trading after the company reported Q2 results.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Today, Sage Therapeutics, Inc.
About SAGE
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a compound that is in Phase II clinical ... [Read more...]
| Industry Biotechnology | IPO Date Jul 18, 2014 |
| CEO Jeffrey Jonas | Employees 298 |
| Stock Exchange NASDAQ | Ticker Symbol SAGE |
Analyst Forecasts
According to 22 analysts, the average rating for SAGE stock is "Buy." The 12-month stock price forecast is 100.55, which is an increase of 34.26% from the latest price.